{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:09:41Z","timestamp":1788826181344,"version":"build-2803163510"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R01AG069352"],"award-info":[{"award-number":["1R01AG069352"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["23 to 09258"],"award-info":[{"award-number":["23 to 09258"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["23 to 23507"],"award-info":[{"award-number":["23 to 23507"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Private equity acquisition of medical practices has been associated with increased prices and use of lucrative treatments. Using Medicare data from 2015 to 2021, we compared the prevalence of low-value cancer treatments between private equity\u2013owned and non\u2013private equity\u2013owned practices. The 5 low-value treatments were (1) granulocyte colony-stimulating factors for low-risk chemotherapy, (2) denosumab for castration-sensitive prostate cancer, (3) nab-paclitaxel for breast or lung cancer, (4) the addition of bevacizumab for ovarian cancer, and (5) biologic agents with biosimilar alternatives. The primary outcome was receipt of a low-value treatment. Comparing patients diagnosed when their oncologist was vs was not practicing at a private equity\u2013owned address, adjusted prevalence differences of low-value treatments were \u22122.8 percentage points (95% confidence interval [CI]\u2009=\u2009\u22125.5 to \u22120.2) for granulocyte colony-stimulating factors, +3.7 percentage points (95% CI\u2009=\u2009\u22127.3 to 14.7) for denosumab, \u22120.7 percentage points (95% CI\u2009=\u2009\u22123.9 to 1.5) for nab-paclitaxel, \u22126.5 percentage points (95% CI\u2009=\u2009\u221212.5 to \u22120.4) for bevacizumab, and \u22122.9 percentage points (95% CI\u2009=\u2009\u22126.0 to 0.2) for biologics. Overall, private equity ownership was not associated with increased prevalence of low-value cancer treatments.<\/jats:p>","DOI":"10.1093\/jnci\/djag093","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:42:27Z","timestamp":1774615347000},"page":"1758-1761","source":"Crossref","is-referenced-by-count":1,"title":["Use of low-value cancer care in practices acquired by private equity firms"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3639-3515","authenticated-orcid":false,"given":"Aaron P","family":"Mitchell","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7885-6317","authenticated-orcid":false,"given":"Miranda B","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0813-3433","authenticated-orcid":false,"given":"Caroline","family":"Carlin","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Community Health, University of Minnesota , Minneapolis, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8585-1802","authenticated-orcid":false,"given":"Kevin","family":"Tyan","sequence":"additional","affiliation":[{"name":"Harvard Medical School Department of Medicine, , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9347-494X","authenticated-orcid":false,"given":"Maryam","family":"Mooghali","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine , New Haven, CT,","place":["United States"]},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Department of Medicine, Yale School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Zakaria","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3845-3606","authenticated-orcid":false,"given":"Reshma","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine , New Haven, CT,","place":["United States"]},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Department of Medicine, Yale School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7574-0677","authenticated-orcid":false,"given":"Jeah","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Health Administration and Policy, College of Public Health, George Mason University , Fairfax, VA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2026090719564089700_djag093-B1","doi-asserted-by":"publisher","first-page":"qxae047","DOI":"10.1093\/haschl\/qxae047","article-title":"Life cycle of private equity investments in physician practices: an overview of private equity exits","volume":"2","author":"Singh","year":"2024","journal-title":"Health Aff Sch"},{"key":"2026090719564089700_djag093-B2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jamadermatol.2019.1634","article-title":"Trends in private equity acquisition of dermatology practices in the United States","volume":"155","author":"Tan","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2026090719564089700_djag093-B3","doi-asserted-by":"crossref","first-page":"e222886","DOI":"10.1001\/jamahealthforum.2022.2886","article-title":"Association of private equity acquisition of physician practices with changes in health care spending and utilization","volume":"3","author":"Singh","year":"2022","journal-title":"JAMA Health Forum"},{"key":"2026090719564089700_djag093-B4","doi-asserted-by":"crossref","first-page":"e245376","DOI":"10.1001\/jamahealthforum.2024.5376","article-title":"Sale of private equity\u2013owned physician practices and physician turnover","volume":"6","author":"Berquist","year":"2025","journal-title":"JAMA Health Forum"},{"key":"2026090719564089700_djag093-B5","doi-asserted-by":"crossref","first-page":"e075244","DOI":"10.1136\/bmj-2023-075244","article-title":"Evaluating trends in private equity ownership and impacts on health outcomes, costs, and quality: systematic review","volume":"382","author":"Borsa","year":"2023","journal-title":"BMJ"},{"key":"2026090719564089700_djag093-B6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1377\/hlthaff.2024.00687","article-title":"Variation in hospital salary expenditures and utilization changes after Private Equity Acquisition, 2005-19","volume":"44","author":"Kannan","year":"2025","journal-title":"Health Aff (Millwood)"},{"key":"2026090719564089700_djag093-B7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamainternmed.2022.0004","article-title":"Association of physician management companies and private equity investment with commercial health care prices paid to anesthesia practitioners","volume":"182","author":"La Forgia","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2026090719564089700_djag093-B8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijrobp.2025.07.1444","article-title":"Private equity acquisitions in oncology: impact on market share and prices","volume":"124","author":"Abdelhadi","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026090719564089700_djag093-B9","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/jama.2024.28565","article-title":"Who should own Americans\u2019 health care?","volume":"333","author":"Himmelstein","year":"2025","journal-title":"JAMA"},{"key":"2026090719564089700_djag093-B10","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1001\/jama.2023.23147","article-title":"Changes in hospital adverse events and patient outcomes associated with private equity acquisition","volume":"330","author":"Kannan","year":"2023","journal-title":"JAMA"},{"key":"2026090719564089700_djag093-B11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamainternmed.2023.0334","article-title":"Private equity acquisition of oncology clinics in the US from 2003 to 2022","volume":"183","author":"Tyan","year":"2023","journal-title":"JAMA Intern Med"},{"key":"2026090719564089700_djag093-B12","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1200\/JCO-24-01907","article-title":"Use of low-value cancer treatments in Medicare advantage versus traditional Medicare","volume":"43","author":"Jung","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026090719564089700_djag093-B13","doi-asserted-by":"crossref","first-page":"e075512","DOI":"10.1136\/bmj-2023-075512","article-title":"Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study","volume":"383","author":"Mitchell","year":"2023","journal-title":"BMJ"},{"key":"2026090719564089700_djag093-B14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/1475-6773.13970","article-title":"Implementation of resource use measures in Medicare Advantage","volume":"57","author":"Jung","year":"2022","journal-title":"Health Serv Res"},{"key":"2026090719564089700_djag093-B15","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1001\/jamaoncol.2015.3151","article-title":"Risk adjusting survival outcomes in hospitals that treat patients with cancer without information on cancer stage","volume":"1","author":"Pfister","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026090719564089700_djag093-B16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ophtha.2023.09.029","article-title":"Association of private equity firm acquisition of ophthalmology practices with Medicare spending and use of ophthalmology services","volume":"131","author":"Braun","year":"2024","journal-title":"Ophthalmology"},{"key":"2026090719564089700_djag093-B17","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMsa2306609","article-title":"Hospital prices for physician-administered drugs for patients with private insurance","volume":"390","author":"Robinson","year":"2024","journal-title":"N Engl J Med"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag093\/67661177\/djag093.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/9\/1758\/67661177\/djag093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/9\/1758\/67661177\/djag093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:56:49Z","timestamp":1788825409000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/9\/1758\/8560075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":17,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag093","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,3,30]]}}}